FTC won't study pharmacy benefit managers

A motion on whether the Federal Trade Commission should study pharmacy benefit managers and how they've affected drug prices and pharmacy operations failed to get a majority vote today among FTC commissioners, who voted 2-2.

Why it matters: The PBM industry, which has been heavily consolidated over the past several years, gets a pass from antitrust scrutiny for now.